HC Wainwright Initiates Coverage on Coya Therapeutics (NASDAQ:COYA)

Research analysts at HC Wainwright assumed coverage on shares of Coya Therapeutics (NASDAQ:COYA) in a research report issued to clients and investors on Monday, Marketbeat Ratings reports. The firm set a “buy” rating and a $18.00 price target on the stock. HC Wainwright’s target price would indicate a potential upside of 193.16% from the stock’s previous close.

Other analysts also recently issued research reports about the stock. Rodman & Renshaw initiated coverage on shares of Coya Therapeutics in a research report on Thursday, June 13th. They set a “buy” rating and a $18.00 target price for the company. Chardan Capital reissued a “buy” rating and set a $14.00 target price on shares of Coya Therapeutics in a research note on Wednesday, June 5th.

Coya Therapeutics Stock Down 2.2 %

Shares of Coya Therapeutics stock opened at $6.14 on Monday. The stock has a market cap of $89.75 million, a price-to-earnings ratio of -7.22 and a beta of 0.58. Coya Therapeutics has a twelve month low of $3.21 and a twelve month high of $10.69. The company’s fifty day moving average is $6.32 and its 200 day moving average is $7.56.

Coya Therapeutics (NASDAQ:COYA) last released its quarterly earnings results on Monday, August 12th. The company reported ($0.19) EPS for the quarter. The business had revenue of $3.43 million during the quarter. As a group, equities analysts anticipate that Coya Therapeutics will post -1.17 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Coya Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. AIGH Capital Management LLC increased its stake in shares of Coya Therapeutics by 92.6% in the 4th quarter. AIGH Capital Management LLC now owns 1,031,977 shares of the company’s stock valued at $7,381,000 after acquiring an additional 496,183 shares in the last quarter. Greenlight Capital Inc. raised its holdings in shares of Coya Therapeutics by 172.2% during the fourth quarter. Greenlight Capital Inc. now owns 1,274,026 shares of the company’s stock valued at $9,441,000 after purchasing an additional 805,959 shares during the period. Vanguard Group Inc. boosted its position in shares of Coya Therapeutics by 772.3% during the 1st quarter. Vanguard Group Inc. now owns 847,490 shares of the company’s stock worth $8,407,000 after purchasing an additional 750,338 shares in the last quarter. Gilbert & Cook Inc. acquired a new stake in shares of Coya Therapeutics in the 2nd quarter valued at about $61,000. Finally, Renaissance Technologies LLC bought a new stake in Coya Therapeutics in the 2nd quarter valued at about $101,000. 39.75% of the stock is owned by institutional investors and hedge funds.

About Coya Therapeutics

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.